What are the precautions for Imaavy (nipocalimab-aahu)?

In the clinical study of Imaavy (nipocalimab-aahu) in the treatment of generalized myasthenia gravis (gMG), warnings and precautions such as infection, allergic reactions, and infusion-related reactions have emerged. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. Infection: Imaavy may increase the risk of infection. In patients with active infection, dosing should be delayed until the infection resolves. Monitor for clinical signs and symptoms of infection during treatment with Imaavy. If serious infection occurs, treat appropriately and consider suspending use of this product until infection resolves.

(1) Latent viral infections: Patients receiving Imaavy may be at increased risk of activation of latent viral infections (such as herpes zoster).

(2) Immunization: The safety of live vaccine immunization and the immune response to vaccination during treatment with Imaavy are unknown. Because Imaavy causes a decrease in IgG levels, live vaccines are not recommended during treatment with Imaavy. Before starting treatment with Imaavy, assess the need for age-appropriate vaccinations according to immunization guidelines.

2. Hypersensitivity reactions: In clinical trials, hypersensitivity reactions, including angioedema, anaphylaxis, rash, urticaria, and eczema, were observed in patients treated with Imaavy. Allergic reactions are mild or moderate and occur within 1 hour to 2 weeks after administration.

Management of allergic reactions depends on the type and severity of the reaction. Monitor patients for clinical signs and symptoms of allergic reaction during treatment with Imaavy and for 30 minutes after completion of dosing. If an allergic reaction occurs during administration, stop the Imaavy infusion and take appropriate supportive measures if necessary. Imaavy is contraindicated in patients with a history of severe allergy to nipocamab or any of Imaavy's excipients.

3. Infusion-related reactions: In clinical trials, infusion-related reactions, including headache, flu-like illness, rash, nausea, fatigue, dizziness, chills, and erythema, were observed in patients treated with Imaavy. In studies, infusion-related reactions were mild to moderate in severity and occurred within 1 hour to 2 days after dosing.

Monitor patients duringImaavy treatment and for 30 minutes after each infusion. If a serious infusion-related reaction occurs, the Imaavy infusion should be discontinued and appropriate treatment initiated. Consider the risks and benefits of reinstating Imaavy after serious infusion-related reactions. If mild to moderate infusion-related reactions occur, patients may require close clinical observation, slower infusion rates, and premedication.

In short, inImaavy’s treatment of generalized myasthenia gravis, infection, allergic reactions and infusion-related reactions are all important factors that cannot be ignored. Medical staff need to fully understand and manage these potential side effects when performing treatment to ensure that patients can enjoy the therapeutic effects while minimizing the occurrence of adverse reactions.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8886274c-f2b2-48af-85c1-2f90bfe304b8##